Market Place
Market Place
Sourcing Support
Stock Recap #PipelineProspector
Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD
Pharma indices settled slightly lower in September after four months of solid gains. The three major
Pipeline Prospector Aug 2024: Otsuka buys Jnana, Lilly’s market cap gains by over US$ 108 bn post new guidance
As summer draws to a close, pharma and biotech indices posted their fourth consecutive month in the
Pipeline Prospector July 2024: Indices continue to climb; Lilly buys Morphic for US$ 3.2 bn, Kisunla bags FDA nod
The biotechnology sector ended in the green for the third month in a row in July, significantly outp
Pipeline Prospector June 2024: FDA approves Merck’s next-gen pneumococcal vaccine, Verona’s COPD therapy
The pharma indices were back in the black in May, and the good streak continued through June with th
Pipeline Prospector May 2024: J&J inks two deals for eczema drugs; Novo scores trial wins in hemophilia, kidney disease
Pharma indices have rebounded after ending March and April in the red. May saw the Nasdaq Biotechnol
Pipeline Prospector April 2024: Indices dip amid muted Q1 results; Vertex acquires Alpine Immune for US$ 4.9 bn
Pharma indices had begun to recede in March. Their red streak accelerated in April with the Nasdaq B
Pipeline Prospector March 2024: FDA approves pathbreaking NASH drug from Madrigal, two meds for PAH
March was clearly a month of drug approvals, as the US Food and
Drug Administration (FDA) went on a
Pipeline Prospector Feb 2024: Novo’s parent buys Catalent for US$ 16.5 bn, FDA okays Iovance’s cell therapy
February was a good month for the pharma sector, complete with some important deals, successes from
Pipeline Prospector Jan 2024: Vertex’s non-opioid painkiller succeeds in trials; Sanofi buys Inhibrx for US$ 2.2 bn
The New Year got off to a stable start, with some good news
trickling in from clinical trials and B
Pipeline Prospector 2023 highlights: Obesity drugs perk up Lilly, Novo sales; ADCs spur dealmaking
The year 2023 was marked by volatility. The good news is that despite factors like inflation, intere
Pipeline Prospector Nov 2023: Lilly, Novo post sharp rise in Q3 sales; AbbVie buys ImmunoGen for US$ 10.1 billion
Through much of 2023, markets remained volatile, with pharma indices managing to inch up only in som
Pipeline Prospector Oct 2023: Disappointing Q3 results, attacks on Israel, Gaza drag pharma indices down further
October was a gloomy month that saw Palestinian militant group Hamas attack Israel in the first week
Pipeline Prospector Sept 2023: Pharma indices dip further; Merck, BioCardia hit by trial setbacks
Biotech indices underperformed in September. The downward trend witnessed in August got accelerated
Pipeline Prospector Aug 2023: Trial gains, Q2 results push up Lilly, Novo stocks even as indices dip
After a buoyant July, when all the three pharma indices inched up by 2 percent, August proved to be
Pipeline Prospector July 2023: Indices inch up on better than expected Q2 results
July saw all three biotech indices inch up by 2 percent as several drugmakers announced th
Pipeline Prospector June 2023: Lilly, J&J, Merck stocks gain even as indices slip into red
June was a lackluster month for pharma stocks. The Nasdaq Biotechnology Index (NBI) was down 0.7 per
Pipeline Prospector May 2023: Uncertainty over debt ceiling deal impacts indices
In April, the biotech indices
had crawled up post the drubbing in March due to the collapse of Sili
Biotech indices inch up post SVB bloodbath; Covid drugmakers report drop in Q1 sales
In March, the collapse of Silicon Valley Bank (SVB) had dragged the biotech indices down. SVB had ma
Pipeline Prospector March 2023: Silicon Valley Bank collapse hits biotech indices; Pfizer buys out Seagen
Biotech indices have witnessed a lot of volatility throughout 2022 and 2023. Just when they were beg
Pipeline Prospector Feb 2023: Low demand for Covid drugs hammers down Lilly, Moderna stocks
The year had opened on a buoyant note. But February quickly dashed any hopes of a market rebound and
Pipeline Prospector Jan 2023: Mega cap drugmakers face rout at bourses even as biotech indices inch upwards
After facing the worst year since 2008, biotech indices opened 2023 on a positive note. All the thre
Pipeline Prospector Dec 2022: Biotech indices fall on close of a volatile year
The year 2022 was a difficult one for the biotech sector. Marked with geopolitical unrest, rising in
Pipeline Prospector November 2022: Positive news on RSV vaccines, cancer drugs bring gains for Big Pharma
After bouncing back in October, biotech indices
continued to rally in November. The Nasdaq Biotechn
Pipeline Prospector October 2022: Biotech indices bounce back on positive Q3 results
After a bearish September, biotech indices
bounced back last month on the back of some bullish tren
Pipeline Prospector September 2022: Biotech stocks dip on ‘end of pandemic’ remarks
It’s most certainly been a highly volatile year thus far. After rising in June, July and Augus
Pipeline Prospector Aug 2022: US law to curb inflation spooks big pharma stocks
Biotech stocks have been looking up since June this year. The
trend continued through August with t
Pipeline Prospector July 2022: Indices continue to climb as drugmakers post better than expected Q2 results
After a tough first five months, biotech stocks
finally began to look up in June
this year. And Ju
Pipeline Prospector June 2022: Strong industry fundamentals bring gains for biotech indices
It’s been a lackluster year for pharma stocks. Barring March, all other months until May saw b
